RxSight, Inc. (RXST)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$6.38-2.45%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
RxSight aims for $120 to $135 million revenue in 2026. Gross margin should stay near 71%. They control costs within $150 to $160 million. A new deal with Alcon could boost growth.
The company lost money in recent quarters. Revenue growth is slow and costs remain high. The new Alcon deal may not improve profits soon.
The price is about 51% below our fair value near $14. Analysts expect 7.7% revenue growth. We see risk in profit and cost control.
Breaks if: The Alcon collaboration fails or is delayed beyond 1 year
Collaborate with Alcon to develop and commercialize light-adjustable presbyopia-correcting intraocular lenses, including next-generation LAL, LAL+, and LAL Toric lenses.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity with a medium confidence level. The current thesis state is cautious, as recent financial performance has been weak and the company is navigating a transition in leadership.
The market appears to be pricing in a justified valuation that reflects RXST's weak execution quality compared to peers. The expectations gap suggests that the market anticipates some challenges ahead, but not the full extent of fragility.
Management is on track to achieve its revenue and gross margin targets, but operating expenses remain a mixed picture. Recent changes show a decline in company momentum and quality, indicating potential challenges in maintaining performance.
The future performance of RXST hinges on several factors, including guidance updates from management, broader economic conditions, and the performance of key sector peers. Any cuts to guidance or continued weakness in the jobs market could negatively impact sentiment.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. RxSight reported lower revenue of $30.9 million. This is an 18.5% decrease year-over-year. Investors expect lower near-term revenue growth because of this decline. Gross profit margin expanded to 76.1%, up from 74.8%. This suggests improved profitability despite revenue challenges. Operating expenses increased to $41.3 million, widening the net loss to $15.9 million.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 disclosures including 2026-Q2 and a July 2026 press release. The collaboration with Alcon includes up to $200 million upfront and milestone payments, with product pipeline updates on next-generation lenses. This reflects a strategic growth initiative with ongoing development and commercialization efforts, showing active progress but early in trajectory.
“Entered into a strategic collaboration with Alcon to develop and commercialize light-adjustable presbyopia-correcting intraocular lenses.”
Breaks if: Gross margin falls below 70% in FY26
Breaks if: Operating expenses exceed $160 million in FY26
Breaks if: Annual revenue falls below $120 million in FY26
Over the next 1 to 3 years, RXST's performance will depend on its ability to navigate risks while leveraging sector momentum. Not investment advice.